PTC Therapeutics Inc. is planning to sell $100 million of its common shares in a public offering.
The South Plainfield, N.J.-based company also plans to grant the underwriter a 30-day option to buy up to an additional $15 million of common shares.
Credit Suisse is sole book-running manager for the offer.
PTC Therapeutics is a biopharmaceutical company developing therapies for rare disorders. The company offers Translarna and Emflaza for treating patients with Duchenne muscular dystrophy.
